Denali Therapeutics (DNLI) Expected to Announce Earnings on Thursday

Key Points

• Denali Therapeutics is expected to release its Q2 2025 earnings on August 7, with analysts predicting a loss of ($0.73) per share.
• The company recently reported a ($0.78) EPS for the previous quarter, missing estimates and showing a year-over-year increase in losses.
• Institutional investors have strengthened their positions in Denali Therapeutics, with 92.92% of the stock currently owned by such investors.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Denali Therapeutics to post earnings of ($0.73) per share and revenue of $5.64 million for the quarter.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter in the previous year, the business posted ($0.68) EPS. On average, analysts expect Denali Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI traded down $0.39 during mid-day trading on Friday, reaching $13.44. 1,762,097 shares of the company's stock were exchanged, compared to its average volume of 1,381,198. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -5.03 and a beta of 1.36. Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $33.33. The business's fifty day moving average price is $14.20 and its 200-day moving average price is $15.93.

Insider Buying and Selling at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 495,282 shares of Denali Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the sale, the chief executive officer owned 253,071 shares of the company's stock, valued at approximately $3,796,065. This trade represents a 66.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DNLI. Empowered Funds LLC increased its position in shares of Denali Therapeutics by 11.0% during the first quarter. Empowered Funds LLC now owns 20,639 shares of the company's stock worth $281,000 after acquiring an additional 2,052 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Denali Therapeutics by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company's stock valued at $1,210,000 after purchasing an additional 3,432 shares during the last quarter. Woodline Partners LP increased its holdings in Denali Therapeutics by 13.5% during the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company's stock worth $1,543,000 after purchasing an additional 13,517 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Denali Therapeutics by 58.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company's stock worth $22,732,000 after purchasing an additional 614,555 shares during the last quarter. 92.92% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on DNLI shares. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. Wedbush decreased their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. Robert W. Baird decreased their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. Finally, HC Wainwright lowered their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Denali Therapeutics has an average rating of "Buy" and a consensus price target of $33.71.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.